

July 21, 1999

Dockets Management Branch (HFA-305)
Food & Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20857-0003

8314 '99 JUL 27 AIO:35

Louise Arganbright
1664 W. Jones Crk. Rd.
Grants Pass, OR 97526

To The FDA:

RE: DOCKET NO. 98N-1265 (98N-1265)

I send this ltr. as a consumer of healthcare services to register my concern & disapproval of the Memorandum of Understanding as published by the FDA on Jan. 21, 1999.

I am requesting that the MOU be amended to permit consumers the right to receive prescribed compounded drugs that are formulated in another state & a separate state from that in which they reside.

I am also requesting that the MOU be amended to permit pharmacists the right to suggest alternatives to physicians & patients including alternative drugs that may be better suited to treating a particular problem or symptom, especially if the alternative is a compounded drug.

By severely limiting the interstate distribution of compounded prescriptions, with no concern for limiting the same distribution practices for non-compounded prescriptions, the MOU establishes a bias towards particular pharmaceutical companies & threatens the economic survival of specialty pharmacies further restricting consumer choices. Equal treatment under the law is called for & the MOU must be amended!!

As a healthcare consumer, there should be no restrictions to the delivery of a compounded medication prescribed for me regardless of where I may live or my travel. The MOU must be amended!!!

Signed:


Louise Arganbright


State of Residence:

Oregon

98N-1265

C 4527


Louise Arganbright
1664 W. Jones Crk. Rd.
Grants Pass, OR 97526



Docket Management Branch (HFA-305)

FDA

5630 Fishers Lane, Room 1061

Rockville, MD 20857-0003

RE: Docket No. 98N-1265